Gang Song

Dr. Gang Song is the founder of Pillar Biosciences, who co-invented Pillar Biosciences’ SLIMamp® technology. He subsequently co-founded Affyimmune Therapeutics, a cellular immunotherapy company, and is also a Venture Partner at ORI Capital. Previously, Dr. Song held positions of increasing responsibility at LabCorp (previously Genzyme Genetics) and IQuum (subsequently acquired by Roche Molecular Diagnostics). Dr. Song completed his postdoctoral training in Timothy Springer's lab at Harvard Medical School and received his Ph.D. from Shanghai Medical College of Fudan University, China.